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Abstract
Background: The follow-up of differentiated thyroid cancers is based on neck ultrasonography and serum thyroglobulin assay (Tg), during 
l-T4 therapy and after recombinant human TSH administration; this test appears quite expensive, considering that only a small percentage of 
patients with undetectable Tg on TSH suppression therapy shows a response after TSH stimulation.
Objectives: The aim of our study was to verify whether low levels of serum thyroglobulin at the time of remnant ablation (A-Tg) associated with 
undetectable thyroglobulin levels on TSH suppression (S-Tg), have sufficient negative predictive value for recurrence of disease, thus avoiding 
rh-TSH test in Differentiated Thyroid Cancer patients.
Methods: we retrospectively enrolled 975 DTC patients treated with thyroidectomy+131-I remnant ablation showing undetectable S-Tg 
measured after 12 months follow-up. The availability of A-Tg and rh-TSH stimulated Tg (R-Tg) obtained 1 year later were considered as inclusion 
criteria. Patients with positive circulating Ab-Tg and/or histological dedifferentiation were excluded. Patients were subdivided in high and low risk 
of recurrence according to the criteria proposed by the European Thyroid Cancer Taskforce.
Results: Using rh-TSH test as gold standard, the NPV for A-Tg<10 µg/L was 98.5% in group A (low risk patients) and 95.5% in group B 
(high risk patients); it significantly raised to 99.2% in group A (p-value 0.03) and 99.3% in group B (p-value 0.02) when the association between 
A-Tg<10 µg/L and S-Tg<0.6 µg/L was considered. When we evaluated the whole population the negative predictive value was 97% for A-Tg<10 
µg/L alone, raising to 99.3% when associated with S-Tg<0.6 µg/L (p-value<0.008).
Conclusion: our data confirmed the very high negative predictive value of the association between low levels of A-Tg and undetectable S-Tg 
in the early risk stratification of differentiated thyroid cancer patients, leading to avoid rh-TSH test with an important economic impact.
Keywords: Ablation thyroglobulin; Suppressive thyroglobulin; Differentiated thyroid carcinoma; rh-TSH test
Abbreviations: RAI: I-131 remnant ablation; DTC: Differentiated thyroid cancer; Tg: Thyroglobulin; THW: Thyroid hormone withdrawal; R-Tg: 
rh-TSH stimulated thyroglobulin; S-Tg: Suppressive thyroglobulin; A-Tg: Ablation thyroglobulin; NPV: Negative predictive value; PPV: Positive 
predictive value; WBS: 131-I Whole body scan; AbTg: Anti-Tg serum antibodies; DF: Disease free; PRD: Persistence/recurrence of disease; 
ROC: Receiver Operative Characteristic; CI: Confidence interval
Introduction
Total or near-total thyroidectomy followed by I-131 remnant ablation 
(RAI) and thyroid hormone suppression therapy are usually considered 
as the standard approach for the initial treatment of differentiated thyroid 
carcinoma (DTC) [1-3]. Follow-up management is based on physical 
examination, neck ultrasonography and serum thyroglobulin assay 
(Tg). In particular, the undetectable stimulated Tg, which is measured 
during thyroid hormone withdrawal (THW) or after recombinant 
human TSH (rh-TSH) administration (R-Tg), is the main evidence of the 
patient’s recovery [2-4]. Unfortunately, this test appears quite expensive, 
considering that only a small percentage of patients with undetectable 
Tg on TSH suppression therapy (S-Tg) shows a response after TSH 
stimulation [5].
Despite the low risk of DTC-related death, a long-term follow-up is 
required since the rates of disease recurrence (up to 20% of patients) 
have been reported also many years after initial treatment [1]. In this 
context the number of patients who need monitoring for possible disease 
recurrence is very high and the early identification of patients at high risk 
of relapse is crucial in order to set a more aggressive treatment and closer 
follow-up. The initial staging is based on the clinicopathological system 
( ISSN 2380-548X )
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which has been elaborated by American Joint Cancer Committee/Union 
Internationale Contre le Cancer (AJCC/UICC) [6]. The main problem of 
this approach is that this system was designed to predict mortality [7], 
whereas a good follow-up program has to take into account the different 
risk of persistent or recurrent disease after the initial treatment. To 
overcome this limitation, the American Thyroid Association (ATA) [3] 
and the European Thyroid Association (ETA) [2] Consensus Statement 
subdivided thyroid cancer patients into different risk levels based on 
tumor-related parameters integrated with other clinical features, including 
histotype and age. Furthermore, these initial ATA/ETA risk estimates can 
be significantly improved through the assessment of patients’ response to 
initial therapy, thereby providing a dynamic risk evaluation as proposed 
by Tuttle et al. [8] and Castagna et al. [9].
In this context, some studies have observed that serum Tg levels 
measured just before RAI after total or near-total thyroidectomy (A-
Tg) had the capability to predict the persistent/recurrent disease vs the 
disease-free status [10,11]. Particularly, a meta-analysis [12] including 
fifteen studies involving 3947 patients with DTC, showed 94% of negative 
predictive value (NPV) for A-Tg<10 µg/L. Moreover, a study [13] 
demonstrated that in patients at high risk of cancer there was a significant 
correlation between the increase of A-Tg levels and the risk of relapse, 
showing a positive predictive value (PPV) of 97% when patients have 
A-Tg>50 µg/L falling to 55% when 10<A-Tg<50 µg/L.
Furthermore, we evaluated [14] the association of A-Tg<10 µg/L and 
undetectable S-Tg concentrations (<0.6 µg/L) during the first year after 
RAI on 169 low risk DTC patients and we observed that NPV value 
increased to 97.1%, raising to 100% when 2 years follow-up outcome was 
considered. These data suggest that rh-TSH test could be avoided in low 
risk DTC patients with low levels of A-Tg and undetectable S-Tg.
The aim of our study was to confirm these results in a wider population 
and to assess whether low A-Tg levels associated with undetectable S-Tg 
concentrations maintained a high NPV for recurrence of disease, leading 
to avoid rh-TSH test, also in high-risk DTC patients.
Subjects and Methods
In this study we retrospectively evaluated 975 consecutive patients 
treated in the section of Nuclear Medicine at the Mauriziano Hospital of 
Turin from a total of about 2100 subjects treated with RAI from January 
2001 to January 2011, in order to obtain a minimum follow up of 2 years. 
Since more than 80% of total RAI in Piedmont Region are performed 
in this Institution, this homogeneous population can be considered 
as representative of DTC behaviour during the last decade in a north-
western region of Italy.
All patients underwent: 1) total thyroidectomy (patients with clinically 
apparent nodal disease also underwent compartment-oriented neck 
dissection); 2) RAI (2960-3700 MBq) during THW 4-6 weeks after 
surgery; 3) 131-I whole body scan (WBS) 3-5 days after RAI therapy; 
4) L-T4 suppressive therapy (serum TSH levels<0.2 µIU/mL); 4) rh-
TSH test 6-12 months after RAI. At least 2 years follow-up was available 
for each patient with mean follow-up of 5.4 years after thyroidectomy. 
Patients with positive anti-Tg serum antibodies (AbTg) and histological 
dedifferentiation during follow-up were excluded.
Serum Tg levels were measured after four weeks THW immediately 
before RAI (A-Tg) and after 3-6-12 months on L-T4 suppressive therapy 
(S-Tg). Then, patients received one injection of rh-TSH (0.9 mg i.m., 
Thyrogen®, Genzyme Corporation, Sanofi Company, Cambridge, MA) for 
two consecutive days; serum samples for TSH and Tg measurements were 
collected on days 0 (before first rh-TSH administration), 3 and 4. Neck 
ultrasonography was performed 3, 6 and 12 months after RAI.
Tg was measured using an immunoradiometric test (Cis Bio 
International, France) with a lower detection limit of 0.2 µg/L and a 
functional sensitivity of 0.7 µg/L. In our series only 6 patients showed 
R-Tg values of 0.7 µg/L and all of them resulted as disease free according 
to the criteria described below. Indeed, in order to make comparable 
our data with most literature reports, we considered 0.6 µg/L as the cut-
off value between not measurable and measurable Tg levels, according 
to Mazzaferri et al. [4,15]. TSH and AbTg serum levels were measured 
using a chemiluminescent immunoassay (Access Immunoassay Systems, 
Beckman Coulter®, Inc, Brea, CA).
The patients were divided in high, low and very low risk according 
to the criteria proposed by the European Thyroid Cancer Taskforce [2] 
(Table 1). However, since the last group included only few patients as 
usually they did not undergo RAI treatment, the population was divided 
in group A (low risk+very low risk) and group B (high risk) as reported in 
table 2. In the whole population and in each subgroup the NPV value of 
A-Tg<10 µg/L alone and associated with undetectable S-Tg was evaluated.
Patients with negative neck ultrasonography and R-Tg<0.6 µg/L were 
considered as disease free (DF). Patients with R-Tg>2 µg/L, S-Tg>0.6 µg/L 
or with imaging evidence of recurrence were classified as persistence/
recurrence of disease (PRD) and underwent further treatments, as surgery 
and/or RAI. Patients with R-Tg between 0.6-2 µg/L were considered 
as equivocal and they were reclassified according to the subsequent 
follow-up outcome. In particular, they were submitted to an additional 
Tg stimulation test with rh-TSH 12 months later. If serum Tg became 
undetectable or remained at the same values of the previous test the 
patient was considered as DF, being most probably due to normal thyroid 
remnant [16].
Post-therapy WBS was performed in all population, while only in 
patients with suspected PRD was conducted a further diagnostic WBS to 
evidence extra-thyroid uptake.
Statistical analysis
Commonly used statistical methods have been applied to describe the 
data (means, standard deviation, range, frequencies, percentage). The 
cut-off levels for A-Tg were selected by Receiver Operative Characteristic 
(ROC) curve analysis. The statistical significance of differences between 
qualitative variables was assessed with Chi square (χ2) test, with Yates 
correction when necessary, or the Fisher’s exact test, while it was evaluated 
with Wilcoxon test between quantitative variables. Sensitivity, specificity, 
NPV and PPV were calculated for A-Tg alone and the association of 
A-Tg and S-Tg using the rh-TSH test as gold standard and the confidence 
interval (CI) was set at 95%. 
All data analyses were performed by the SAS package for Personal 
Computer (SAS Inc. V 8.2, Cary, NC).
Results
The study cohort was made up of 732 (75.1%) female and 243 (24.9%) 
male patients. The mean age at diagnosis was 49.1 ± 14.7 years (range 11-
86 years). The histopatological types consisted of 766 (78.6%) papillary 
carcinoma and 209 (21.4%) follicular carcinoma, including 42 Hürthle 
cell carcinoma. According to epidemiological data of DTC [17-19], males 
had a lower incidence but they showed a more aggressive histological 
phenotype and, consequently, resulted in an increased risk of PRD. 
Clinical and outcome data of patients are reported in table 2.
As reported in literature [12], we used the threshold of A-Tg<10 µg/L 
(sensitivity 78.4%, specificity 83.8%, NPV 96.9%), which was similar to the 
A-Tg cut-off of 12 µg/L suggested by ROC curve analysis performed on 
our population (figure 1) (sensitivity 81.2%, specificity 79.9%, NPV 97.3%).
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Figure 1: ROC curve to select the optimal threshold of A-Tg values in our population. A-Tg: Tg measured just before RAI after total or near-total 
thyroidectomy. R-Tg: Tg measured after rh-TSH somministration.
Very low risk
(Tot. 42)
Low risk
(Tot. 453)
High risk
(Tot. 480)
Total
(Tot. 975)
Disease free 41 (97.6%) 437 (96.5%) 398 (82.9%) 876 (89.8%)
Persistence/Recurrence of disease 1 (2.4%) 16 (3.5%) 82 (17.1%) 99 (10.2%)
Table 1: Subdivision of patients into three risk categories according to European Thyroid Cancer Taskforce [2].
Group A
(Tot. 495)
Group B
(Tot. 480)
All patients
(Tot. 975)
Disease free 478 (96.6%) 398 (82.9%) 876 (89.8%)
Persistence/Recurrence of disease 17 (3.4%) 82 (17.1%) 99 (10.2%)
Males 107 (21.6%) 136 (28.3%) 243 (24.9%)
Females 388 (78.4%) 344 (71.7%) 732 (75.1%)
Age at diagnosis 47.2 ± 13.4(range 16-79)
51.1 ± 15.7
(range 11-86)
49.1 ± 14.7
(range 11-86)
Years of follow-up 5.6 ± 2.9 5.2 ± 2.9 5.4 ± 2.9
Histological features (papillary/follicular) 389/106(78.6%/21.4%)
377/103
(78.5%/21.5%)
766/209
(78.6%/21.4%)
TNM T1 282 (57.0%) 45 (9.4%) 327 (33.5)
T1a 50 15 65
T1b 99 11 110
T1m 133 19 152
T2 213 (43.0%) 23 (4.8%) 236 (24.2%)
T3 - 383 (79.8%) 383 (39.3%)
T4 - 29 (6.0%) 29 (3.0%)
N1 - 176 (36.7%) 176 (18.0%)
M1 - 10 (2.1%) 10 (1.0%)
A-Tg<10 µg/L 411 (83.0%) 341 (71.0%) 752 (77.1%)
A-Tg>10 µg/L 84 (17.0%) 139 (29.0%) 223 (22.9%)
A-Tg<10 µg/L+S-Tg<0.6 µg/L 402 (81.2%) 328 (68.3%) 730 (74.9%)
A-Tg<10 µg/L+S-Tg>0.6 µg/L L 9 (1.8%) 13 (2.7%) 22 (2.2%)
Table 2: Clinical and pathological patient’s features in group A (very low risk + low risk), group B (high risk) and whole population. TNM classification system 
according to American Joint Committee on Cancer (AJCC) [6]. A-Tg: Tg measured just before RAI after total or near-total thyroidectomy. S-Tg: Tg on TSH 
suppression therapy.
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Post-therapy WBS showed 843/975 (86.5%) and 119/975 (12,2%) 
patients with thyroid and extra-thyroid uptake respectively. All data about 
initial WBS performed and the subsequent follow-up were described in table 3.
Group A + Group B
In the whole population, 876/975 (89.8%) patients were defined as DF 
and 99/975 (10.2%) as PRD (table 2).
Overall, 752/975 (77.1%) showed A-Tg<10 µg/L (table 4); among them 
729/752 (96.9%) were DF and 23/752 (3.1%) were PRD. Based on these 
data, the NPV of A-Tg alone was 96.9%, with sensitivity of 78.4% and 
specificity of 83.8% (table 5).
Furthermore, 730/975 (74.9%) patients showed A-Tg<10 µg/L and 
S-Tg<0.6 µg/L, of which 725/730 (99.3%) patients resulted as DF and 
5/730 (0.7%) were PRD. The distribution of patients is reported in figure 
2. Therefore, when A-Tg<10 µg/L was associated with S-Tg<0.6 µg/L the 
NPV raised to 99.3% (p-value<0.008), with a simultaneous increase in 
sensitivity (78.4% vs 95.4%), maintaining the same specificity (83.8% vs 83.2%).
Group A
495/975 subjects were included in group A (table 2); 478/495 
(96.6%) were defined as DF based on R-Tg<0.6 µg/L and negative neck 
ultrasonography.
411/495 (83.0%) showed A-Tg<10 µg/L (table 4); among them 403/411 
(98.1%) were DF and 8/411 (1.9%) were PRD. In this group of patients the 
NPV of A-Tg alone was 97.9%.
Moreover, 402/495 (81.2%) patients showed A-Tg<10 µg/L and 
S-Tg<0.6 µg/L. In these 402 patients the NPV, sensitivity and specificity 
of the association of A-Tg<10 µg/L and S-Tg<0.6 µg/L was 100% (p-value 
0.03), 100% and 85.6% respectively (Table 5).
Group B
480 subjects were included in group B (table 2); 398/480 patients 
(82.9%) were defined as DF based on R-Tg<0.6 µg/L and negative neck 
ultrasonography.
Overall, 341/480 (71.0%) showed A-Tg<10 µg/L (table 4); among them 
the NPV of A-Tg<10 µg/L was 95.7%. In this group, the association of 
A-Tg<10 µg/L and S-Tg<0.6 µg/L showed a NPV of 98.5% (p-value 0.02), 
with a sensitivity of 94.5% and a specificity of 80.4% (Tables 4 and 5).
Discussion
The follow-up of patients with DTC is mostly based on serum Tg 
measurement for identifying patients with persistent or recurrent disease. 
Detectable S-Tg levels have been recognized as a good marker of DTC 
recurrence after initial treatment, whereas R-Tg is probably the most 
important means to define remission of disease [2-3].
Recent studies [10-14] assessed the predictive value of A-Tg showing 
a significant correlation between A-Tg levels and the values of stimulated 
Tg after rh-TSH. In particular, a meta-analysis [12] involving nearly 4000 
patients, confirmed that A-Tg levels can be a useful negative predictor of 
persistent or recurrent DTC, defining a cut-off value of 10 µg/L as optimal 
sensitivity and specificity. About 70% of patients had Tg levels below this 
threshold and the overall NPV was 94.2%.
Our previous study [14] extended this observation and showed that low 
risk DTC patients with A-Tg levels<10 µg/L combined with undetectable 
S-Tg had a NPV for disease recurrence of 97.1%, rising to 100% when 2 
years follow-up was taken into account; in particular none of patients with 
A-Tg<10 µg/L showed a significant response to rh-TSH (R-Tg>2 µg/L).
In the present study, we retrospectively evaluated the prognostic 
significance of A-Tg, alone and associated with S-Tg, both in each class 
of risk according to European Thyroid Cancer Taskforce criteria [2], 
and in the whole population of DTC patients. Our data showed that 
A-Tg<10 µg/L has a NPV of 96.9% in the whole population, according 
to the data reported in literature [2]. When the A-Tg was associated 
with undetectable S-Tg levels, the NPV significantly raised to 99.3% 
(p-value<0.008) with a considerable sensitivity improvement (78.4% 
vs 95.4%) maintaining a similar specificity (83.8% vs 83.2%). Moreover, 
these results were reproduced in both risk groups, when the patients were 
subdivided in two groups based on different risk of persistent/recurrent 
disease. In group A (low risk+very low risk of recurrence) A-Tg associated 
with S-Tg levels showed a NPV of 100%, while in group B (high risk of 
recurrence) it resulted slightly lower (98.5%) compared to the whole 
population, however confirming itself as a reliable prognostic index.
According to these data, we hypothesize that it could be possible for 
a group of patients to avoid the rh-TSH test during follow-up based on 
A-Tg<10 µg/L and S-Tg<0.6 µg/L values. In particular, in our population 
730/876 (83.3%) DF patients could have avoided the expensive Tg 
stimulation test (figure 2).
Since in our study 478/495 (96.6%) of very low risk and low risk 
patients (group A) and 398/480 (82.9%) of high risk patients (group B) 
resulted as DF, we believe that risk stratification according to European 
Thyroid Cancer Taskforce [2] assigns too many subjects to high risk group 
without a really PRD evidence during follow-up. This concept is also 
reported by Castagna et al. [9] showing that 53% of high risk patients can 
be subsequently reclassified as low risk after 8-12 months follow-up from 
the initial treatment.
Altogether, the association between A-Tg and S-Tg can be considered 
an important completing factor for initial risk stratification of DTC 
patients, beyond clinical and histological parameters. As a matter of fact, 
the association between A-Tg<10 µg/L and S-Tg<0.6 µg/L may correctly 
identify 77.1% (725/975) of patients as DF, regardless of the ETA risk 
stratification. The combination of these two parameters had only 5/975 
(0.5%) false negative; these cases may be early detected as relapsed/
recurrent disease during the following one-year follow-up on the basis of 
the increasing value of S-Tg and/or ultrasound evaluation.
In our study, A-Tg>10 µg/L was considered a criterion for the early 
classification of patients at high risk of PRD. As illustrated in figure 2, 
223/975 (22.9%) patients showed A-Tg>10 µg/L. Among them 147/223 
(65.9%) patients were DF and 76/223 (34.1%) patients were PRD. 
THYROID UPTAKE 843
CERVICAL UPTAKE 60
Disease free 35
54
Disease free after more treatments 19
Persistence of the disease 6 6
DISTANT UPTAKE 59
Disease free 15
24
Disease free after more treatments 9
Persistence of the disease 35 35
NO UPTAKE 13
975
Table 3: Post-therapy WBS uptake and the consequence follow-up in the 
all population.
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R-Tg + R-Tg – NPV p-value
Group A +
Group B
(Tot. 975)
A-Tg<10 µg/L
(752 patients) 23 (3.1%) 729 (96.9%) 96.9 % <0.008
A-Tg<10 µg/L + S-Tg<0.6 µg/L
(730 patients) 5 (0.7%) 725 (99.3%) 99.3%
Group A
(Tot. 495)
A-Tg<10 µg/L
(411 patients) 8 (1.9%) 403 (98.1%) 97.9% 0.03
A-Tg<10 µg/L + S-Tg<0.6 µg/L
(402 patients) 1 (0.2%) 401 (99.8%) 100%
Group B
(Tot. 480)
A-Tg<10 µg/L
(341 patients) 15 (4.4%) 326 (95.6%) 95.7%
0.02
A-Tg<10 µg/L + S-Tg<0.6 µg/L
(328 patients) 4 (1.2%) 324 (98.8%) 98.5%
Table 4: Negative Predictive Value (NPV) of A-Tg<10 µg/L alone and associated with undetectable S-Tg in the whole population, in group A and in group 
B. A-Tg: Tg measured just before RAI after total or near-total thyroidectomy. S-Tg: Tg on TSH suppression therapy. R-Tg: Tg measured after rh-TSH 
somministration.
Group A
% (CI)
Group B
% (CI)
Group A + B
% (CI)
A-Tg<10 µg/L
PPV
NPV
Sensitivity
Specificity
13.1 (4.6-21.6)
97.9 (89.1-100)
53.3 (28.1-78.6)
86.2 (78.1-94.3)
49.2 (40.4-57.9)
95.7 (86.6-100)
83.6 (75.1-92.1)
81.0 (73.8-88.4)
37.3 (30.3-44.3)
96.9 (87.3-100)
78.4 (69.8-87.0)
83.8 (75.2-92.4)
A-Tg<10 µg/L
+
S-Tg<0.6 µg/L
PPV
NPV
Sensitivity
Specificity
21.4 (11.8-31.0)
100 (89.1-100)
100 (78.2-100)
85.6 (76.8-94.5)
51.5 (43.0-59.9)
98.5 (92.0-100)
94.5 (89.3-99.7)
80.4 (77.4-95.0)
41.2 (34.4-47.9)
99.3 (90.2-100)
95.4 (91.1-99.8)
83.2 (78.9-92.8)
Table 5: Sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) in group A, B and whole population. A-Tg: Tg 
measured just before RAI after total or near-total thyroidectomy. S-Tg: Tg on TSH suppression therapy.
Figure 2: Patients distribution based on A-Tg and S-Tg values in the 
whole population. A-Tg: Tg measured just before RAI after total or near-
total thyroidectomy. S-Tg: Tg on TSH suppression therapy.
A-Tg>10 µg/L values can identify only 76.8% (76/99) of patients with PRD 
compared to the percentage obtained by ETA risk classification system 
(82.8%). However, when we considered A-Tg>10 µg/L combined with 
S-Tg>0.6 µg/L, we correctly identified 66/69 (95.5%) patients at higher 
risk of recurrence, thus obtaining a good initial risk stratification for PRD, 
which led to a more accurate therapeutic choice planning.
A limitation of this study is the employment of serum Tg assay with 
lower detection limit of 0.2 µg/L and functional sensitivity of 0.7 µg/L. 
However it has to be considered that higher sensitive assays have been 
widely used in the clinical practice only in the last years. Nevertheless 
we choose to begin the enrollement in 2001 in order to obtain a large 
population with a long time of follow up. Another limit is represented by 
the lack of data about remnant entity, which presented certain variability 
since the surgery was performed in various centers.
On the other hand, an advantage of this study is the fact that our 
Institution performs more than 80% of total RAI in Piedmont Region, 
allowing to consider this population as homogeneous and representative 
of DTC behaviour in the last 10 years in this area.
In conclusion, our data confirm the usefulness of the association 
between A-Tg and S-Tg in the early risk stratification of DTC patients, 
leading to avoid rh-TSH test in a wide number of subjects and to a more 
accurately therapeutic choice planning, with a remarkable economic 
impact. We suggest that the association between A-Tg<10 µg/L and 
S-Tg<0.6 µg/L combined to negative neck ultrasonography can be 
considered as sufficient parameters for classifying DTC patients as DF.
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